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Abstract
Background: Globally, the monitoring of prompt and effective treatment for malaria with artemisinin combination
therapy (ACT) is conducted largely through household surveys. This measure; however, provides no information on
case management processes at the health facility level. The aim of this review was to assess evidence from health
facility surveys on malaria prescribing practices using ACT, in the presence and absence of ACT stock, at time and
place where treatment was sought.
Methods: A systematic search of published literature was conducted. Findings were collated and data extracted on
proportion of patients prescribed ACT and alternative anti-malarials in the presence and absence of ACT stock.
Results: Of the 14 studies identified in which ACT prescription for uncomplicated malaria in the public sector was
evaluated, just six, from three countries (Kenya, Uganda and Zambia), reported this in the context of ACT stock.
Comparing facilities with ACT stock to facilities without stock (i) ACT prescribing was significantly higher in all six
studies, increasing by a range of 21.3% in children < 5 yrs weighing ≥ 5 kg (p < 0.001; Kenya 2006) to 51.7% in
children ≥ 10 kg (p < 0.001; Zambia 2006); (ii) SP prescribing decreased significantly in five studies, by a range of
14.4% (p < 0.001; Kenya 2006), to 46.3% (p < 0.001; Zambia 2006); (iii) Where quinine was a reported alternative,
prescriptions decreased in five of the six studies by 0.1% (p = 1.0, Kenya 2010) to 10.2% (p < 0.001; Zambia 2006).
At facilities with no ACT stock on the survey day, the proportion of febrile patients prescribed ACT was < 10% in
five of the nine target groups included in the six studies, with the proportion prescribed ACT ranging from 0 to
28.4% (Uganda 2007).
Conclusions: Prescriber practices vary based on ACT availability. Although ACT prescriptions increased and
alternative anti-malarials prescriptions decreased in the presence of ACT stock, ACT was prescribed in the absence,
and alternative anti-malarials were prescribed in the presence of, ACT. Presence of stock alone does not ensure
that treatment guidelines are followed. More health facility surveys, together with qualitative research, are needed
to understand the role of ACT stock-outs on provider prescribing behaviours and preferences.
Background
Despite progress in malaria control due to the availabil-
ity of effective tools for treatment and prevention, access
to interventions remains inequitable in sub-Saharan
Africa, where an estimated 90% of the malaria-related
mortality is concentrated, in part due to overstretched
and under-resourced health systems [1]. Prompt and
effective treatment of malaria episodes is fundamental to
reducing morbidity and mortality [2]. The importance of
treatment to the control of malaria is highlighted by
various control initiatives and targets: the World Health
Organization recommends treatment within 24 hours of
symptom onset, particularly in children under five years
of age, and the Roll Back Malaria (RBM) partnership
established the target of diagnosing and treating 80% of
malaria patients with an effective anti-malarial within 24
hours of illness onset by 2010 [3].
Traditionally, malaria treatment has relied on the use
of monotherapies, firstly chloroquine and subsequently
amodiaquine (AQ) and sulphadoxine-pyrimethamine
(SP), as first-line therapy [4]. The WHO, following the
development of widespread resistance to these mono-
therapies, has recommended the use of artemisinin-
based combination therapy (ACT) as first-line treatment
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of uncomplicated malaria in sub-Saharan Africa since
2001. By 2009, all African countries had adopted ACT
as the recommended first-line treatment policy [5,6].
Notwithstanding these policy changes, ACT coverage
for episodes of febrile illness in children remains well
below the 80% universal coverage target across Africa
[7]. A summary of national level household survey data
from 2007-2008 presented in the 2009 World Malaria
Report highlights that ACT reached an average of only
15% of children under five years of age with a fever in
the previous two weeks [7]. The RBM partnership
reports coverage ranging from 0-50% amongst children
living in African countries who received any anti-malar-
ial treatment for malaria symptoms, based on adminis-
trative data from 2005 to 2009 [8].
Although highly efficacious, ACT is considerably more
expensive than the monotherapies it replaces; therefore,
parasitological diagnosis by microscopy or rapid diag-
nostic test (RDT) is now recommended to reduce mis-
diagnosis, ensure targeted treatment and prevent the
development of resistance due to unnecessary drug pres-
sure [9,10]. Procurement and supply chain management
(PSM) procedures required to ensure ACT is delivered in
the right quantity, to the right patient, at the right time,
are the same as for other drugs used to treat malaria and
other conditions. However, added complexities include:
the availability of ACT in three to four different weight-
specific dosing packages; the relatively short (two years)
lifespan of the drug; and the recommendation of parasito-
logical diagnosis using RDTs prior to treatment [11,12].
Consequently, ensuring the availability of these different
components at public health facilities requires greater
precision in quantification and supply management than
for previous first-line treatments.
There are several processes contributing to the
achievement of a successful coverage outcome which
begin with treatment being sought for the febrile child.
The source from which treatment is sought (for exam-
ple, public sector health facilities, community delivery
points, the retail sector, or traditional healers) influences
the likelihood of whether or not a child will be pre-
scribed or given an ACT [13]. Where parasitological
diagnosis is available, treatment with ACT should be
based upon the outcome of the test. However, in the
absence of availability of parasitological diagnosis febrile
children suspected of malaria should be given ACT
unless there is a clear alternative diagnosis to malaria.
Every febrile child accessing a public health facility
where a) malaria parasites are identified, or b) no clear
alternative diagnosis is made, should receive an ACT.
Globally, the monitoring of prompt and effective ACT
treatment is conducted largely through household sur-
veys. This coverage measure; however, provides no
information on the facilitators of high coverage or the
reasons for low coverage; in particular, the processes
that occur at health facility or provider level are not
investigated. The main processes in ACT delivery within
the health facility are diagnosis, prescription, dispensing
and communication between the health worker and the
carer. To fully understand the malaria treatment path-
way, health facility surveys are required to determine
whether these processes are occurring. It is also impor-
tant to investigate the potential predictors of effective
delivery processes, which can be broadly categorised
into characteristics of the health workers, characteristics
of the children and their carer, and characteristics of the
health facility.
Furthermore, assessments of prescribing and dispen-
sing practices in the absence of data relating to ACT
stock at the time and place of presumptive or parasito-
logical diagnosis may underestimate the intent of
health workers to prescribe recommended first-line
treatment. Poor ACT coverage and a failure of health-
care workers to prescribe them may not always be
attributable to lack of adherence to guidelines or fail-
ures of training programmes, but may also reflect the
quality of the PSM or weaknesses within health sys-
tems. Assessments of prescribing practices and of the
processes involved in treatment outcomes in the
absence of stock information may lead to misguided
assumptions and the development and implementation
of interventions targeted at health workers that fail to
demonstrate significant impact. The aim of this review
is to assess evidence from health facility surveys on the
extent to which prescribing of ACT and alternative
anti-malarials in Africa varies in the presence and
absence of stock of ACT.
Methods
Search strategy
A systematic search of published literature was
conducted using the electronic database PUBMED
(Medline). The review was conducted using various
combinations of the following search terms: malaria,
fever, anti-malarial, ACT, artemisinin-based, private sec-
tor, retail sector, community, health facility, quality of
care, case-management, stock-out, shortage, stock, sup-
ply chain, distribution, prescrib*, dispens* (see Addi-
tional file 1 for full details). The final full search was
conducted in June 2010. Grey literature was found by
conducting internet searches for organizations managing
malaria-related programmes, including ACTwatch,
AMFm and Stop Stock-Outs. The final grey literature
search was conducted in July 2010. All studies were
imported into EndNote X3 for screening against the
inclusion criteria.
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Inclusion criteria
Studies were considered eligible for inclusion based on
the following criteria:
1) Disease of focus was uncomplicated malaria
2) Country of focus was in Africa
3) Country’s first-line anti-malarial at the time of the
study was an ACT
4) The study included an assessment of anti-malarial
prescribing at the time treatment was sought
5) Prescribing practices were assessed in the context
of ACT stock (with health facility surveys used to
collect stock data)
Where intervention studies targeting provider prac-
tices or product supply management included a control
group, data was only extracted for the control arm. Stu-
dies involving public or private health facilities were eli-
gible for inclusion. Public facilities included
government-run hospitals, health centres, health posts,
NGO- or mission-run hospitals and health centres and
community-based providers. The formal private sector
included providers with professional qualifications and
education, including doctors, clinical officers and nurses
working for profit. Prescribing practices eligible for
inclusion were practices for febrile patients with parasi-
tologically-confirmed malaria or where a presumptive
malaria diagnosis was made. It was assumed that where
an anti-malarial was prescribed the diagnosis, whether
presumptive or confirmed, was correct. Where a febrile
patient was diagnosed parasitologically-negative, pre-
scribing practices for these patients were not included
in the analysis.
Analysis of studies
For eligible studies, data relating to anti-malarial pre-
scribing practices; ACT stock, frequency and duration of
stock-outs; and analysis of ACT stock-out coping strate-
gies (alternative anti-malarial prescribing practices) were
extracted and imported into a results framework devel-
oped in Excel.
Provider prescribing behaviours were included only for
presumptive or biologically-confirmed malaria cases that
is anti-malarial prescribing practices for parasitologi-
cally-diagnosed malaria-negative patients was not
considered.
Findings were collated and analysed to determine: 1)
proportion of patients prescribed ACT at all facilities
and stratified by presence or absence of ACT stock; 2)
proportion of patients prescribed a non-ACT anti-
malarial at all facilities and stratified by the availability
(presence or absence) of ACT stock. The p-value and
95% confidence intervals for the differences between
prescribing practices where analysis was restricted to
facilities with stock compared with practices where ana-
lysis was restricted to facilities without stock on survey
day were obtained using a chi-squared test in R version
2.11.1 (confidence intervals not adjusted for clustering
at facility level).
Results
The published literature search identified 734 studies
and an additional ten reports were included from the
grey literature. Of these, 14 studies assessed prescribing
practices, but only six assessed prescribing practices in
the context of facility ACT stock, and were thus
included in the final analysis (Figure 1).
All six selected studies were cross-sectional studies
conducted at public health facilities (see Additional file
2). Study procedures included exit interviews, clinical
observations, facility surveys and health worker inter-
views [14-19]. Two studies were conducted in Kenya
[14,19], one in Uganda [18] and three in Zambia
[15-17]. All countries had adopted artemether-lumefan-
trine (AL) as their first-line ACT: Kenya in 2006,
Uganda in 2004 and Zambia in 2002. Across the six stu-
dies prescribing practices were defined for nine popula-
tions: one study reported on prescribing for any age
group [15], one presented data for children weighing ≥
5 kg [19], two studies presented data based on age
group (< 5 years or ≥ 5 years) [14,18] and two of the
studies presented paediatric treatment data with respect
to weight (< 5 kg and ≥ 5 kg) [16,17]. In this review,
these nine populations were defined as the target groups
in the analysis of results.
ACT stock
Five of the six studies provided data on frequency and
length of ACT stock-out (Additional file 2). One study
provided no data on frequency or length of stock-out
but presented prescribing practices at facilities regard-
less of ACT stock and at facilities with ACT stock [14].
The proportion of facilities with complete ACT stock
out of all four weight-specific packs on the survey day
ranged from 5.7% of facilities in Kenya in 2010 to 48.9%
in Zambia in 2004 [16,17]. Three studies reported pro-
portion of time spent with ACT stock-out, which ranged
from approximately 30% of the year in a study from
Zambia in 2006 to 38% of the time between October to
December 2009 in Kenya [16,18].
ACT prescribing at all facilities
Across facilities, regardless of ACT availability, the pro-
portion of febrile patients that were prescribed an ACT
ranged from 10.7% of children ≥ 10 kg in 2004 in Zam-
bia to 66.4% of children < 5 yr in 2007 in Uganda
[14,16] (Table 1). In 2006, four years after Zambia’s
malaria drug treatment policy change, a repeat cross
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sectional survey reported increased ACT prescribing
practices at public health facilities for children ≥ 10 kg
(10.7% to 42.2%; p < 0.001) compared with 2004 [16,17].
The highest proportion of the target group prescribed
an ACT was reported at facilities in Kenya in 2010, six
years after malaria treatment policy change, with 62.3%
of children < 5 yrs and 63.5% of patients ≥ 5 yrs pre-
scribed an ACT [14]. Similar relatively high levels of
ACT prescribing were reported in Uganda in 2007, with
66.4% of children < 5 yrs and 56.2% of patients ≥ 5 yrs
prescribed an ACT [18].
ACT prescribing in the presence and absence of stock
Where analysis of prescribing practices was restricted to
facilities with ACT stock, prescribing increased across
all studies compared to prescribing in all facilities
regardless of the presence or absence of ACT stock.
Where analysis was restricted to patients seen at facil-
ities without ACT stock, ACT was still prescribed in
eight out of the nine target groups (Table 1). However,
estimates of the proportion of febrile patients prescribed
ACT were lower in facilities with stock-outs of ACT in
comparison with facilities with stock, with the propor-
tion of patients prescribed ACT at facilities without
stock ranging from 0% of children weighing ≥ 10 kg in
Zambia 2004 to 28.4% of patients ≥ 5 yrs in Uganda
2007 [17,19].
Where analysis of prescribing practices was restricted
to facilities with ACT and compared to ACT prescribing
at facilities without ACT stock, a statistically significant
increase in the proportion of febrile patients prescribed
ACT was observed in all target groups across the six
studies. The greatest difference in proportion of febrile
patients prescribed ACT in facilities with ACT com-
pared to facilities without ACT was 51.7% (58.6% to
6.9%; p < 0.001) for patients < 5 yrs, weighing ≥ 10 kg
in the 2006 Zambian study [17]. A second study con-
ducted in Zambia in 2006 showed a 37.7% increase in
ACT prescribing where analysis was restricted to facil-
ities with stock (44.7%) and compared to facilities with-
out stock on the survey day (7%; p < 0.001) [15]. In
studies conducted in Kenya in 2006 and 2010, Zambia
in 2004 and in Uganda in 2007, there were similar sig-
nificant differences in the proportion of febrile patients
Figure 1 Results of study inclusion process.
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prescribed ACT when restricting analyses to facilities
with ACT stock and comparing these estimates with
analyses of prescribing at facilities without ACT stock
[18,19].
Alternative anti-malarial prescribing
Alternative anti-malarials were prescribed in all of the
study sites, although these anti-malarials varied across
countries and studies (Table 2, 3). Quinine (QN) was
prescribed across all countries but prescriptions were
low, at less than 10%. Other alternative anti-malarials
prescribed and presented included artemether-lumefan-
trine+QN, AQ, SP, AQ+SP, chloroquine (CQ) and CQ
+SP. Across all facilities the proportion of febrile
patients prescribed any alternative anti-malarial ranged
from 8.6% in Kenya in 2010 to 72.3% for children ≥ 10
kg in Zambia in 2004 (Table 2) [16,17]. Disaggregated
by type of alternative anti-malarial, the proportion of
patients prescribed an alternative ranged from 0.4% of
children < 5 yrs prescribed SP in 2007 in Uganda [18]
to 67.5% of children ≥ 10 kg prescribed SP in 2004 in
Zambia [16] (Table 3).
Alternative anti-malarial prescribing in the presence and
absence of ACT
Where analysis of prescribing practices was restricted to
facilities with ACT stock, a decrease in alternative anti-
malarial prescribing, compared to alternative anti-malar-
ial prescribing at all facilities regardless of the presence
or absence of ACT stock, was observed in all studies
(Table 2). A decrease in the proportion of febrile
patients prescribed QN was observed in six out of the
nine target groups and for SP in seven out of eight tar-
get groups across the six studies (Table 3). Prescribing
practices for AQ in Kenya 2006 CQ+SP and CQ for
patients < 5 yrs in Uganda 2007 also decreased, albeit
marginally for some target groups [14,18,19].
At facilities with no ACT stock, the proportion of feb-
rile patients prescribed any alternative anti-malarials was
generally significantly higher in comparison with
Table 1 ACT Prescribing at facilities with and facilities without ACT stock
Country, Year % (No.) of patients diagnosed with uncomplicated malaria/fever and prescribed ACT
At all facilities,
% (n)
At facilities with ACT stock,
%(n)
At facilities with no ACT stock,
%(n)
% differencea
(95% Confidence Intervalc; p-value)
Kenya, 2006 [19] 26.4%
(248/940)
28.1%
(243/866)
6.8%
(5/74)
21.3%
(14.1%, 28.5%; p < 0.001)
Kenya, 2010 [14] < 5 yrs < 5 yrs < 5 yrs < 5 yrs
62.3%
(592/950)
64.1%
(585/913)
18.9%
(7/37)
45.2%
(30.8%, 59.6%; p < 0.001)
≥ 5 yrs ≥ 5 yrs ≥ 5 yrs ≥ 5 yrs
63.5%
(746/1175)
65.7%
(730/1112)
25.4%
(16/63)
40.3%
(28.3%, 52.2%; p < 0.001)
Uganda, 2007 [18] < 5 yrs < 5 yrs < 5 yrs < 5 yrs
66.4%
(306/461)
69.4%
(297/428)
27.3%
(9/33)
42.1%
(24.7%, 59.7%; p < 0.001)
≥ 5 yrs ≥ 5 yrs ≥ 5 yrs ≥ 5 yrs
56.2%
(415/739)
60.3%
(388/644)
28.4%
(27/95)
31.9%
(21.4%, 42.3%; p < 0.001)
Zambia, 2004 [16] ≥ 10 kg ≥ 10 kg ≥ 10 kg ≥ 10 kg
10.7%
(42/394)
21.9%
(42/192)
0/202 21.9%
Zambia, 2006 [17] 5-9 kg 5-9 kg 5-9 kg 5-9 kg
27.0%
(149/552)
41.0%
(144/351)
2.5%
(5/201)
38.5%
(32.6%, 44.5%; p < 0.001)
≥ 10 kg ≥ 10 kg ≥ 10 kg ≥ 10 kg
42.2%
(231/547)
58.6%
(219/374)
6.9%
(12/173)
51.7%
(44.9%, 58.3%; p < 0.001)
Zambia, 2006 [15]b 33.9%
(494/1457)
44.7%
(465/1040)
7%
(29/417)
37.7%
(33.7%, 41.8%; p < 0.001)
a Difference is the proportion of patients who received ACT at facilities with stock minus the proportion of patients who received ACT at facilities with no ACT
stock
b Analysis restricted to facilities where diagnostics were available, test negative results excluded from analysis
c Confidence interval not adjusted for clustering at facility level
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facilities with ACT in stock on the day of the survey,
increasing by a range of 13% for patients in Kenya in
2010 to 54.3% for patients ≥ 10 kg in Zambia in 2006
[16,18] (Table 2, 3). Where results were disaggregated
by type of alternative anti-malarial, the exception to this
was prescribing of QN in Zambia 2004 and Uganda
2007 for patients ≥ 5 years of age, of CQ, SP and other
anti-malarials in Uganda in 2007, of QN, AQ+SP and
other anti-malarials in Kenya in 2006 and of AL+QN
and QN in Kenya in 2010 [14,16,18,19] (Table 3). The
greatest difference in proportion of alternative anti-
malarials prescriptions at facilities without ACT stock
compared with facilities with stock was observed in the
proportion of febrile patients prescribed SP; the greatest
difference in proportion of febrile patients prescribed SP
in facilities with and without ACT stock was 46.3%
(21.9% to 68.2%; p < 0.001) for patients 5-9 kg and
44.2% (13.6% to 57.8%; p < 0.001) for patients ≥ 10 kg
in Zambia in 2006 [17]. In Uganda in 2007, the propor-
tion of febrile patients prescribed CQ+SP was higher in
facilities that had no ACT stock than when compared to
facilities with ACT stock, increasing by 34.3% (5.1% to
39.4%; p < 0.001) for children < 5 yrs and by 25.2%
(14.8% to 40% p < 0.001) for patients ≥ 5 yrs [18]. Simi-
larly, in Kenya in 2006, the proportion of febrile patients
prescribed AQ was higher in facilities that had no ACT
stock than at facilities with ACT stock, increasing by
24.1% (36.7% to 60.8%; p < 0.001) [19].
Discussion
ACT stock-outs were a common occurrence across stu-
dies included in this review, ranging from 5.7% to 48.9%
of facilities experiencing total ACT stock-out on the day
of the survey; where percentage of time with ACT
stock-out was reported, chronic problems were indi-
cated with facilities in Zambia in 2006 reporting ACT
stock out for 30% of the year and facilities in Kenya in
2010, 38% reporting total ACT stock out between Octo-
ber to December 2009 [16,18].
ACT prescribing for uncomplicated malaria was con-
siderably below the RBM target of 80% across all stu-
dies. One could predict that if providers know there is
no ACT stock in their facility they will be less likely to
prescribe it and more likely to fall back upon the tradi-
tional mono-therapies from the pre-ACT era; however
stock cannot wholly explain provider behaviour given
Table 2 Alternative Anti-Malarial Prescribing in the Presence and Absence of ACT Stock
Country, Year % (No.) of patients diagnosed with uncomplicated malaria/fever and prescribed Alternative (non-ACT) Anti-Malarial
At all facilities,
% (n)
At facilities with ACT stock, %
(n)
At facilities with no ACT stock, %
(n)
% differencea
(95% Confidence Intervalc; p-
value)
Kenya, 2006 [19] 50.5% (475/940) 47.8%
(414/866)
82.4%
(61/74)
-34.6%
(-44.6%, -24.6%; p < 0.001)
Kenya, 2010 [14] 8.6% (183/2125) 8%
(162/2025)
21%
(21/100)
-13%
(-21.6%, -4.4%; p < 0.001)
Uganda, 2007
[18]
< 5 yrs < 5 yrs < 5 yrs < 5 yrs
19.5%
(90/461)
16.4%
(70/428)
60.6%
(20/33)
-44.2%
(-62.9%, -25.6%; p < 0.001)
≥ 5 yrs ≥ 5 yrs ≥ 5 yrs ≥ 5 yrs
26.7% (197/739) 22.5%
(145/644)
54.7%
(52/95)
-32.2%
(-43.3%, -21.1%; p < 0.001)
Zambia, 2004 [16] ≥ 10 kg ≥ 10 kg ≥ 10 kg ≥ 10 kg
72.3% (285/394) 56.8%
(109/192)
87.1% (176/202) -30.3%
(-39.3%, -21.5%, p < 0.001)
Zambia, 2006 [17] 5-9 kg 5-9 kg 5-9 kg 5-9 kg
43.5% (240/552) 24.2%
(85/351)
77.1%
(155/201)
-52.9%
(-60.6%, -45.2%; p < 0.001)
≥ 10 kg ≥ 10 kg ≥ 10 kg ≥ 10 kg
34.6% (189/547) 17.4% (65/374) 71.7%
(124/173)
-54.3%
(-62.5%, -46.1%; p < 0.001)
Zambia, 2006 [15]
b
36.6% (533/
1457)
23.1%
(240/1040)
70.3% (293/417) -47.2%
(-52.4%, -41.9%; p < 0.001)
a Difference is the proportion of patients who received alternative anti-malarials at facilities with ACT stock minus the proportion of patients who received
alternative anti-malarials at facilities with no ACT stock
b Analysis restricted to facilities where diagnostics were available, test negative results excluded from analysis
c Confidence interval not adjusted for clustering at facility level
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that not all malaria cases in facilities with ACT in the
studies were prescribed ACT and in some studies ACT
prescription continued in facilities despite ACT stock-
outs. Although absence of ACT stock provided an
explanation for much of the non-ACT prescribing beha-
viour, alternative anti-malarials were prescribed where
ACT was available, particularly in studies conducted in
the early years of ACT policy adoption.
This review highlights that, regardless of stock, ACT
prescription increased and prescription of alternative
anti-malarials decreased the longer after ACT policy
introduction the study was conducted. Zambia was
among the first countries to adopt ACT as first-line
treatment for malaria in 2002 [20]; repeat cross-sec-
tional studies indicate that four years post-policy
change, ACT prescribing practices had increased signifi-
cantly. In Kenya, where ACT was adopted as first-line
in 2006, the study conducted in 2010 reported much
higher levels of ACT prescribing than the study con-
ducted in the same year as the introduction of the new
policy. These findings support evidence that initial adop-
tion of new anti-malarial policy can be slow due to a
multitude of factors [21,22], including provider percep-
tions and practices [23-25]; however, ultimately policy
maturation can lead to improved operational implemen-
tation and increased policy adherence by providers
[17,26].
Challenges associated with changing national drug
policies and successful translation of policy to practice
are not new [27,28]. Prior to the implementation of
ACT as first-line treatment, many malaria patients failed
to access anti-malarial treatment, with evidence that
providers failed to prescribe them [26,29]. ACT is how-
ever, more expensive compared with traditional mono-
therapies and available in four weight-specific packs,
adding cost and complexity to PSM systems and hence
making the successful transition to ACT as first-line
therapy even more challenging [20]. These more com-
plex PSM systems also place an increased burden on
weaker health systems, where the infrastructure and
capacity to manage drug procurement and supplies need
to be strengthened to ensure effective and efficient ACT
delivery. Failure to address weaknesses of health and
PSM systems results in insufficient stock of essential
medicines at point of care. Improving coverage of and
access to essential medicines therefore relies not only on
provider prescribing and dispensing practices but also
on the health system and the quality of the PSM sys-
tems within it.
It is important to note here that the results of this
review focus on prescription, which may not necessarily
reflect the drug or dosage that is dispensed, and that
stock levels are also likely to influence dispensary level
outcomes. Within the studies included in this review,
only one study evaluated healthcare providers’ ACT dis-
pensing practices in the presence and absence of
weight-specific ACT packages [14]. Dispensing practices
in this study in Kenya in 2010 suggest that providers
that prescribe ACT are familiar with treatment guide-
lines: where ACT is out of stock, providers combine
pills or cut packs to ensure the appropriate weight-spe-
cific dose is dispensed. Where ACT is available, these
practices decrease [14].
Similarly, it should be noted that for the two studies
that presented data according to the result of a malaria
diagnostic test (Kenya, Zambia), the anti-malarial pre-
scribing practices in the presence and absence of ACT
were only considered for malaria-positive cases and for
patients where no diagnostic test was performed but
were prescribed an anti-malarial. This was done to
maintain as much consistency with the other four stu-
dies where only patients with a malaria diagnosis were
included, even though these were diagnosed presump-
tively. It was, therefore, assumed that all diagnosis was
correct (whether presumptive or confirmed), and that
no providers prescribed an anti-malarial for a non-
malaria patient. It is acknowledged that this is an over-
simplification of provider malaria diagnosis and treat-
ment behaviour [30,31], however the primary objective
of this paper is to understand the influence of ACT
stock rather than diagnostic tests on prescribing
behaviour.
There is a dearth of information on the factors asso-
ciated with increased ACT prescribing; some evidence
suggests that in-service ACT training, availability of wall
charts and access to national guidelines are not signifi-
cantly associated with decisions to prescribe ACT
[17,18] while other studies report that in-service ACT
training is significantly associated with ACT prescribing
[19]. A qualitative study from Kenya documents fear of
stock-outs as limiting ACT prescribing practices, with
shortages of different dose packs and erratic supply
causing health workers to ration the drug to those
deemed to have greatest need or who seem most “deser-
ving” [25]. In addition, availability of alternative anti-
malarials while ACT supplies were inadequate confused
health workers about when to prescribe ACT. Thus,
even when ACT is in stock, both uncertainty around
the continuity of ACT supply and the availability of
alternative anti-malarials are factors that seem to influ-
ence provider practice. Multifaceted assessments of pre-
scribing practices that quantitatively evaluate practices
in operational settings and in the context of ACT stock,
and which also collate qualitative evidence of the factors
that influence providers’ decision-making processes,
would lead to a better understanding of practices and to
the development of evidence-based interventions that
improve treatment outcomes [32].
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Table 3 Alternative anti-malarial prescribing at facilities with and without ACT stock
Country, year of
study
Percentage of patients diagnosed with uncomplicated malaria/fever and prescribed alternative anti-malarials to ACT
All facilities, % (n) Facilities with ACT stock,
%(n)
No ACT stock % differencea (95% Confidence Intervalb; p-
value)
Kenya, 2006 [19] AQ AQ AQ AQ
38.6%
(363/940)
36.7%
(318/866)
60.8%
(45/74)
-24.1%
(-36.4%, -11.8%; p < 0.001)
SP SP SP SP
4.4%
(41/940)
3.2%
(28/866)
17.6%
(13/74)
-14.4%
(-23.8%, 4.8%; p < 0.001)
AQ+SP AQ+SP AQ+SP AQ+SP
2.8%
(26/940)
3%
(26/866)
0/74 3%
Other AMc Other AMc Other AMc Other AMc
3.3% (31/940) 3.3% (29/866) 2.7% (2/74) 0.6%
(0.3%, 11%; p = 1.0)
QN QN QN QN
1.5%
(14/940)
1.5%
(13/866)
1.4%
(1/74)
0.1%
(0.16%, 46.6%; p = 1.0)
Kenya, 2010 [14]e AL+QN AL+QN AL+QN AL+QN
<5 yrs:5.8%
(55/950)
≥ 5 yrs:2.6%
(31/1175)
<5 yrs:6%
(55/913)
≥ 5 yrs:2.8%
(31/1112)
<5 yrs:0/37
≥ 5 yrs:0/63
<5 yrs: 6%
≥ 5 yrs: 2.8%
SP SP SP SP
2.6%
(56/2125)
1.9%
(38/2025)
18%
(18/100)
-16.1%(-24.2%,
8%; p < 0.001)
QN QN QN QN
<5 yrs:2.6%
(25/950)
≥ 5 yrs:1.4%
(16/1175)
<5 yrs:2.6%
(24/913)
≥ 5 yrs:1.3%
(14/1112)
<5 yrs:2.7%
(1/37)
≥ 5 yrs:3.2%
(2/63)
<5 yrs:-0.1%
(-0.1%, 41.1%; p = 1.0)
≥ 5 yrs: -1.9%
(-3.6%, .09%; p = 0.2)
Uganda, 2007 [18] CQ+SP CQ+SP CQ+SP CQ+SP
<5 yrs:7.6%
(35/461)
≥ 5 yrs:18%
(133/739)
< 5 yrs:5.1%
(22/428)
≥ 5 yrs:14.8%
(95/644)
< 5 yrs:39.4%
(13/33)
≥ 5 yrs:40.0%
(38/95)
< 5 yrs: -34.3%
(-81.4%, -45.8%;
p < 0.001)
≥ 5 yrs: -25.2%
(-36.1%, -14.4%;
p < 0.001)
CQ CQ CQ CQ
< 5 yrs:2.2%
(10/461)
≥ 5 yrs:3%
(22/739)
< 5 yrs:2.1%
(9/428)
≥ 5 yrs:2.5%
(16/644)
< 5 yrs:3%
(1/33)
≥ 5 yrs:6.3%
(6/95)
< 5 yrs: -0.9%
(-31.1%, 0.1%;
p = 0.5)
≥ 5 yrs: -3.8%
(-9.5%, 1.8%;
p = 0.08)
SP SP SP SP
< 5 yrs:0.4%
(2/461)
≥ 5 yrs:1.0%
(7/739)
< 5 yrs:0.5%
(2/428)
≥ 5 yrs:0.9%
(6/644)
< 5 yrs:0 (0/33)
≥ 5 yrs:1.0% (1/95)
< 5 yrs: 0.5%
≥ 5 yrs: -0.1%
(0.1%, 41.1%; p = 1)
QN QN QN QN
< 5 yrs:5.9% (27/461)
≥ 5 yrs:2.8% (21/739)
< 5 yrs:5.1% (22/428)
≥ 5 yrs:2.5% (16/644)
< 5 yrs:15.2% (5/33)
≥ 5 yrs:5.3% (5/95)
< 5 yrs: -10.1%
(-24.1%, 4%; p = 0.05)
≥ 5 yrs: -2.8%
(-8%, 2.5%; p = 0.2)
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To understand the processes involved in access to
effective ACT treatment and provider coping strategies
in the absence of ACT stock, we propose a framework
of the treatment pathway in the presence and absence
of ACT stock (Figure 2). The framework is supported
by evidence derived from studies included in our review
and highlights alternative prescribing and dispensing
practices that providers may adopt. Understanding these
practices, which healthcare providers adopt them and
why would facilitate the development and implementa-
tion of appropriate interventions that contribute to
improved ACT access and coverage.
This review is subject to limitations. Firstly, despite
systematically searching published and unpublished lit-
erature, only a small number of studies from a single
group of researchers were identified, conducted in only
three African countries, providing a limited evidence
base for discussion. The review is subject to language
and publication bias and data may, therefore, exist that
was not identified in the literature search. In addition,
despite conducting internet searches for organizations
managing malaria-related programmes, organizations
were not contacted directly. There may, therefore, be
grey literature that meets the inclusion criteria that was
not identified in the search and therefore not included
in the review. Cross-sectional surveys themselves have
limitations when investigating prescribing practices
since they only provide a “snapshot” in time and find-
ings may differ if repeated after a relatively short period
of time. As in the studies conducted in Kenya in 2006
and 2010, facility surveys were administered shortly
after the nationwide distribution of AL [14,19]. Studies
conducted at a different period in time may have pre-
sented very different outcomes. Finally, the analysis is
subject to limitations: in the absence of the raw data
sets variance estimation was not conducted, the analysis,
Table 3 Alternative anti-malarial prescribing at facilities with and without ACT stock (Continued)
Other AMd Other AMd Other AMd Other AMd
< 5 yrs:3.5% (16/461)
≥ 5 yrs:1.9% (14/739)
< 5 yrs:3.5% (15/428)
≥ 5 yrs:1.9% (12/644)
< 5 yrs:3.0% (1/33)
≥ 5 yrs:2.1% (2/95)
< 5 yrs: 0.5%
(0.16%,48.9%; p = 1.0)
≥ 5 yrs: -0.2%
(0.19%, 8.2%; p = 0.7)
Zambia, 2004 [16] SP SP SP SP
≥ 10 kg: 67.5% (266/
394)
≥ 10 kg:53.7% (103/192) ≥ 10 kg:80.7% (163/
202)
≥ 10 kg: -27%
(-36.5%, -17.6%; p < 0.001)
QN QN QN QN
≥ 10 kg: 4.8% (19/
394)
≥ 10 kg:3.1% (6/192) ≥ 10 kg:6.4% (13/
202)
≥ 10 kg: -3.3%
(-8%, 1.4%; p = 0.2)
Zambia, 2006 [17] SP SP SP SP
5-9 kg:38.8% (214/
552)
≥ 10 kg:27.6% (151/
547)
5-9 kg:21.9% (77/351)
≥ 10 kg:13.6% (51/374)
5-9 kg:68.2% (137/
201)
≥ 10 kg:57.8% (100/
173)
5-9 kg: -46.3%
(-54.4%, -38.1%; p < 0.001)
≥ 10 kg: -44.2%
(-52.7%, -35.6%; p < 0.001)
QN QN QN QN
5-9 kg:4.7% (26/552)
≥ 10 kg:7.0% (38/547)
5-9 kg:2.3% (8/351)
≥ 10 kg:3.7% (14/374)
5-9 kg:9.0% (18/201)
≥ 10 kg:13.9% (24/
173)
5-9 kg:-6.7%
(-11.3%, -2,%; p < 0.001)
≥ 10 kg:-10.2%
(-16.1%, -4.2%; p < 0.001)
Zambia, 2006 [15]f, g SP SP SP SP
32.8%
(479/1457)
20.4%
(212/1040)
64%
(267/417)
-43.6%
(-41.3%, -31.4%; p < 0.001)
QN QN QN QN
3.7%
(54/1457)
3.7%
(28/1040)
6.2%
(26/417)
-2.5%
(-5.3%, -0.7%; p = 0.003)
N/A Not applicable
a Difference is the proportion of patients who received alternative anti-malarials at facilities with ACT stock minus the proportion of patients who received
alternative anti-malarials at facilities with no ACT stock
b Confidence interval not adjusted for clustering at facility level
cOther AM = Other Anti-malarial, includes DHA, AQ+QN, SP+QN, AL+QN, AQ+SP+QN
dOther AM = Other Anti-malarial, includes AQ+SP, AL+SP, AL+SP+CQ, QN+SP, AL+QN, AL+CQ
e Results are prescribing practices for febrile patients,
f Results based on all age groups,
g Analysis restricted to facilities where diagnositcs were available, test negative results excluded from analysis
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therefore, does not adjust for clustering at the facility
level. Despite these limitations, the findings relating to
ACT prescribing practices are largely consistent in
terms of direction; with ACT prescribing higher where
stock is available and increased prescribing of alternative
anti-malarials in the absence of ACT stock.
This review highlights the importance of quantifying
the availability of ACT stock at the time of treatment
seeking when assessing provider prescribing and dispen-
sing practices as, in the absence of stock data, these
practices are diluted. Facility surveys therefore, although
not an appropriate methodology for stock monitoring,
are valuable tools to assess prescribing and dispensing
practices in the context of stock. Similarly, facility sur-
veys which assess dose-specific stock may prove valuable
in assessments of the accuracy of provider practices.
Where reported, when ACT is prescribed and dispensed,
the quality of prescribing and dispensing practices is
high in studies included in our review with over 80% of
patients prescribed ACT prescribed the recommended
weight-specific ACT dose; in the context of weight-spe-
cific stock data, these practices may prove higher
[14,17,19].
A greater understanding of the factors that influence
providers’ treatment decision-making process in the
context of ACT stock and stock-outs is needed in order
to direct interventions. Since 2009, the WHO has
recommended the use of RDT prior to a malaria diag-
nosis, to reduce misdiagnosis, ensure targeted treatment
and prevent the development of resistance [9,10]. RDTs
not only add further complexity to the PSM of ACT,
they add complexity to the diagnosis and treatment of
malaria. Further research to understand provider pre-
scribing and dispensing practices in the context of both
the presence and absence of ACT and/or RDTs are,
therefore, required. Finally, there is limited research
regarding the effectiveness of referral to alternative pro-
viders and patient coping strategies in the absence of

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Figure 2 Conceptual framework of prescribing and dispensing practices.
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ACT stock. In a study from Kenya, over 30% of patients
who sought care at public facilities failed to access drugs
due to stock-outs at hospital pharmacies and more than
50% of patients issued ACT prescriptions to buy ACT
outside of the hospital pharmacy did not purchase them
[33]. Studies included in our review did not conduct a
follow-up of patients to determine whether they were
referred to alternative providers or whether patients
purchased ACT at alternative locations using prescrip-
tions provided and thus warrants further research. In
addition, none of the studies we identified were con-
ducted in the private sector. With a large proportion of
malaria care-seeking directed at the private or commu-
nity sectors, where access to ACT remain low, under-
standing the ACT prescribing practices of these
providers also requires additional research [26].
Conclusion
This review provides evidence of the influence of ACT
stock and stock-outs on ACT and alternative anti-
malarial prescribing practices. Where ACT is available,
providers will prescribe them yet prescribing remains
suboptimal. In addition, prescription of alternative anti-
malarials continues, despite ACT availability. Provider
prescribing practices in relation to treatment policy are
not always rational and appropriate patient treatment
cannot always be predicted. To adequately address inap-
propriate use of anti-malarials, multifaceted assessments
of provider prescribing and dispensing practices are
required. Patient-level treatment indicators assessed
through household surveys, alone do not provide suffi-
cient evidence to inform policy or programmes. The
processes involved in malaria treatment and the context
within which these processes take place must be evalu-
ated in order for the outcomes to be fully understood
and improved.
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